Neion Bio emerged from stealth with a platform concept to use genetically engineered chickens as protein “bioreactors,” aiming to replace much of the hardware-heavy biomanufacturing model built around CHO cells and large bioreactor facilities. In a Synbiobeta 2026 presentation, cofounder and CTO Samuel Levin argued that standard CHO workflows remain inefficient and expensive despite long-standing industry investment. Neion Bio’s proposed workflow centers on engineering chickens to produce eggs containing target proteins, followed by downstream extraction. The company described the system as autonomous and scalable, and Levin said a small lab-sized farm could theoretically supply production volumes for a blockbuster biologic like Humira. The pitch positions the platform as an economic and operational reset for protein biologics—especially for developers looking to reduce manufacturing bottlenecks and cost-per-gram. While the approach is early-stage from a clinical-manufacturing standpoint, it targets a core constraint for biologics access: the cost and infrastructure required to manufacture therapeutic proteins at scale.